肝癌一线疗法重大突破!这种免疫组合疗法有望改变治疗模式?(3)
2020-02-25 未知 admin
而昨日罗氏Tecentriq/Avastin组合在3期临床试验中获得的积极结果,是首次在3期临床试验中,证明了这一疗法组合在治疗肝细胞癌时产生的协同效应。罗氏表示,将迅速向全球各地的监管机构递交监管申请,包括美国FDA、欧洲药品管理局(EMA)和中国国家药品监督管理局(NMPA),为治疗选择有限的肝癌患者带来新的治疗方法。我们期待抗血管生成药物与免疫检查点抑制剂的组合,不但能够为一线治疗肝细胞癌带来突破,还能够造福其它多种实体瘤患者。
参考资料:
[1] Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma. Retrieved October 21, 2019, from https://www.businesswire.com/news/home/20191020005095/en
[2] Fukumura et al., (2018). Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Review Clinical Oncology, doi: 10.1038/nrclinonc.2018.29
[3] Kudo, (2019). Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer, DOI: 10.1159/000496277
[4] 2019 ESMO | 梁军教授:肝癌免疫治疗一线之争:单药 or 联合. Retrieved October 21, 2019, from https://mp.weixin.qq.com/s/aQmSUZfcO-V_XBYD5puWSA
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛